Iowa Medicaid Audit Exposes $100 Million PBM Overcharges and Creative Spread‑Pricing Workarounds

When Iowa’s Medicaid auditors started digging into prescription‑drug claims from 2019 through 2021, they probably expected a dry spreadsheet of numbers. What they found instead was a textbook case of how a pharmacy‑benefit manager (PBM) can turn ordinary accounting adjustments into a multi‑million‑dollar windfall.

According to the state‑run review, the PBM in question altered the amount of money it paid pharmacies for dispensed drugs, but it didn’t hand the resulting savings back to the state‑run managed‑care plans that were meant to benefit from the lower cost. In short, the agency kept the difference – a sum that tops $100 million.

That figure isn’t just a headline‑grabbing number; it represents money that Iowa taxpayers ultimately shoulder. The audit says the PBM’s moves effectively “obscured the flow of funds,” making it hard for regulators to see exactly who was paying what and, more importantly, where the extra profit was landing.

What makes this episode especially notable is the technique the PBM employed. It resembles the now‑banned practice known as spread pricing – the PBM charges a health plan more for a drug than it reimburses the pharmacy, pocketing the spread. Although Iowa outlawed spread pricing a few years ago, the audit shows the PBM found a workaround: it adjusted reimbursement rates in a way that technically complied with the letter of the law while flouting its spirit.

Auditors described the maneuver as “creative accounting,” a soft phrase that understates the seriousness of the issue. By shifting how and when payments were recorded, the PBM could sidestep the state’s pricing ban, keep the extra cash, and leave little trace for investigators to follow.

Officials aren’t surprised to see similar patterns elsewhere. Earlier audits in other states – including Texas and Ohio – flagged comparable discrepancies, suggesting this isn’t an isolated Iowa problem but a broader industry habit. “What we’re seeing is a playbook that can be replicated,” said a senior auditor who asked to remain unnamed. “If a state bans spread pricing but doesn’t tighten the underlying reimbursement rules, PBMs will find another way.”

The audit also shines a light on the tangled web of players in the prescription‑drug supply chain. PBMs sit between drug manufacturers, pharmacies, insurers and, ultimately, patients (or taxpayers, when we’re talking Medicaid). Their contracts often contain opaque clauses that allow for rebates, fees and adjustment mechanisms that are difficult for outsiders to decipher.

For Iowa’s Medicaid recipients, the practical impact is higher out‑of‑pocket costs and a system that feels less accountable. For the state, it means a larger budget gap that could have been avoided with stricter oversight.

State legislators have already responded with a flurry of bills aimed at tightening reporting requirements, mandating real‑time data sharing, and expanding the definition of spread pricing to capture these new loopholes. Critics, however, warn that overly prescriptive regulations could push PBMs to develop even more sophisticated workarounds.

What’s clear is that the Iowa audit will likely serve as a template for other states looking to police their own Medicaid drug spending. The message to PBMs is simple: you can’t hide forever behind a maze of spreadsheets and technical jargon. When auditors turn on the lights, the numbers have to add up.

Meanwhile, advocacy groups are urging federal lawmakers to consider a nationwide ban on spread pricing, arguing that a patchwork of state rules merely creates a game of “regulatory roulette.” Until then, it seems every state will have to conduct its own forensic deep‑dives into Medicaid data – and hope they catch the next clever accounting trick before the dollars vanish.